Lancet Market Report and Forecast 2025-2034
Description
The global lancet market size was valued at USD 2.21 Billion in 2024, driven by the increasing availability of a big pool of diabetic patients. The market size is anticipated to grow at a CAGR of 10.60% during the forecast period of 2025-2034 to achieve a value of USD 6.05 Billion by 2034.
Global Lancet Market Overview
The lancet is a small medical implement used to prick the skin, particularly for blood sugar monitoring or capillary blood sampling. The growth of the lancet market can be attributed to the availability of a big pool of diabetic patients and the growing incidences of infectious diseases requiring blood testing for diagnosis and therapy, along with increased awareness of diabetes treatment globally.
Rising Prevalence of Diabetes and High Cholesterol
The increasing issue of high cholesterol among people, especially the geriatric population, is contributing to the global lancet market demand. It is estimated that high cholesterol causes 4.4 million deaths every year. It is a major risk factor for heart disease and stroke in both high- and low-income countries. Practices such as consuming a healthy diet, regular exercise, and medication can help reduce high cholesterol.
In June 2023, according to data from the Institute for Health and Metrics Evaluation, over 500 million people across the globe are currently living with diabetes. This chronic disease affects individuals of all ages and genders in every country worldwide. Unfortunately, this number is projected to more than double in the next 30 years, with estimates suggesting that 1.3 billion people will be living with diabetes by then. This increase is expected to be experienced in every country, highlighting the urgent need for effective prevention and management strategies.
The high prevalence of such conditions requires regular checkups so that they can be diagnosed early and treated well. The lancet are used in the devices that are used to diagnose these conditions through blood sampling such as cholesterol testing devices.
Increased Product Launches in the Market
In August 2023, Roche Diabetes Care Japan Co., Ltd. announced the launch of Accu-Chek Pico, a handy and fully disposable lancet device for blood glucose monitoring to enhance diabetes care for older people living with diabetes nationwide. Accu-Chek Pico will be available in medical institutions such as hospitals and retail pharmacies across Japan.
This innovative product, designed for older people with diabetes is poised to enhance diabetes care. Further, the availability in medical institutions and retail pharmacies throughout Japan for this product is expected to potentially increase demand for lancet in the region, bolstering the lancet market growth.
Additionally, in January 2024, Dexcom revealed new details about Stelo, its new continuous glucose monitor (CGM) designed for people with diabetes who do not take insulin. Stelo by Dexcom, a new continuous glucose monitor targeted for people with diabetes who are not on insulin, has been submitted to the FDA. The medical equipment manufacturer also shared updates on the unique features of the wearable, pricing, and the planned rollout timeline for the device. Stelo launch is expected this summer of 2024 if approved successfully.
This may impact the lancet market potentially by reducing the demand for traditional blood glucose monitoring using lancet. CGMs like Stelo offer continuous monitoring without the need for frequent fingerstick tests which may potentially lead to a shift in user preferences and impact the market for lancet used in traditional blood glucose meters.
Rapid Improvements to Provide a Significant Push
In November 2023, Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus on lung disease, announced the validation and launch of a new method of collecting blood specimens for Nodify Lung Nodule Risk Assessment testing. The method uses the FDA-cleared Tasso+™ device, a single-use blood lancing device intended for obtaining capillary whole blood samples from a patient’s upper arm.
The integration of innovative devices like Tasso+™ signals potential growth, as it introduces an efficient and patient-friendly alternative for fetching blood samples, potentially influencing increased adoption and demand in the lancet market.
Increase in FDA Approvals
In October 2023, Sanguina received the approval from the US Food and Drug Administration (FDA) for its haemoglobin test kit, AnemoCheck Home. AnemoCheck Home, which is an in vitro diagnostic device, will be available only through prescription. Sanguina’s disposable test helps users receive precise haemoglobin level readings by carrying out a simple fingerstick blood test. Sanguina is focused on the development of digital and at-home health platforms for quick home-based testing and disease management. The brand is excited to provide a convenient, accurate, and accessible tool to monitor their haemoglobin levels at home. This approval would significantly aid the global lancet market demand as the test requires a simple fingerstick blood sample, propelling the demand for lancets used in home-based testing and aligning with the growing trend of at-home health monitoring and disease management. Globally, around 40% of all children aged 6–59 months, 37% of pregnant women, and 30% of women 15–49 years of age are affected by anaemia.
Global Lancet Market Segmentations
Market Breakup by Type Side Button Lancet
Push Button Safety Lancet
Pressure Activated Safety Lancet
The growth of the market is primarily driven by the increasing incidences of diabetes and high infectious diseases worldwide. However, the danger of needlestick injuries, the reuse of lancets, and the bad reimbursement situation may act as the major market constraints, hampering the lancet market growth.
North America is anticipated to dominate the regional market due to factors such as the increasing healthcare sector, increasing geriatric population, fast financial development, and increased awareness of diabetes treatment are some of the primary factors, which are aiding in the growth of the North America lancet market growth.
In January 2023, Cipla launched a point-of-care testing device for various non-communicable diseases and other medical conditions. Another addition to its product offerings for diagnostics laboratories, Cipla’s device named Cippoint, offers a wide range of testing parameters including cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers. The device is approved by the European In-Vitro Diagnostic Device Directive, thus ensuring reliable testing solutions.
Cippoint – an immunofluorescence-based quantitative analyser, can help healthcare professionals to get test results in 3 to 15 minutes, thus enabling a faster clinical decision-making process.
The introduction of Cipla's point-of-care testing device could increase the demand for lancets as they are commonly used in devices for blood sampling in point-of-care diagnostics, bolstering the market demand. The focus of Cippoint on accessibility in rural and remote areas is further expected to drive the need for lancets in healthcare settings.
Global Lancet Market: Competitor Landscape
In December 2023, BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced it had received 510(k) clearances from the U.S. Federal Drug Administration (FDA) for a novel blood collection device that obtains blood samples from a fingerstick that produce lab-quality results for some of the most commonly ordered blood tests.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Global Lancet Market Overview
The lancet is a small medical implement used to prick the skin, particularly for blood sugar monitoring or capillary blood sampling. The growth of the lancet market can be attributed to the availability of a big pool of diabetic patients and the growing incidences of infectious diseases requiring blood testing for diagnosis and therapy, along with increased awareness of diabetes treatment globally.
Rising Prevalence of Diabetes and High Cholesterol
The increasing issue of high cholesterol among people, especially the geriatric population, is contributing to the global lancet market demand. It is estimated that high cholesterol causes 4.4 million deaths every year. It is a major risk factor for heart disease and stroke in both high- and low-income countries. Practices such as consuming a healthy diet, regular exercise, and medication can help reduce high cholesterol.
In June 2023, according to data from the Institute for Health and Metrics Evaluation, over 500 million people across the globe are currently living with diabetes. This chronic disease affects individuals of all ages and genders in every country worldwide. Unfortunately, this number is projected to more than double in the next 30 years, with estimates suggesting that 1.3 billion people will be living with diabetes by then. This increase is expected to be experienced in every country, highlighting the urgent need for effective prevention and management strategies.
The high prevalence of such conditions requires regular checkups so that they can be diagnosed early and treated well. The lancet are used in the devices that are used to diagnose these conditions through blood sampling such as cholesterol testing devices.
Increased Product Launches in the Market
In August 2023, Roche Diabetes Care Japan Co., Ltd. announced the launch of Accu-Chek Pico, a handy and fully disposable lancet device for blood glucose monitoring to enhance diabetes care for older people living with diabetes nationwide. Accu-Chek Pico will be available in medical institutions such as hospitals and retail pharmacies across Japan.
This innovative product, designed for older people with diabetes is poised to enhance diabetes care. Further, the availability in medical institutions and retail pharmacies throughout Japan for this product is expected to potentially increase demand for lancet in the region, bolstering the lancet market growth.
Additionally, in January 2024, Dexcom revealed new details about Stelo, its new continuous glucose monitor (CGM) designed for people with diabetes who do not take insulin. Stelo by Dexcom, a new continuous glucose monitor targeted for people with diabetes who are not on insulin, has been submitted to the FDA. The medical equipment manufacturer also shared updates on the unique features of the wearable, pricing, and the planned rollout timeline for the device. Stelo launch is expected this summer of 2024 if approved successfully.
This may impact the lancet market potentially by reducing the demand for traditional blood glucose monitoring using lancet. CGMs like Stelo offer continuous monitoring without the need for frequent fingerstick tests which may potentially lead to a shift in user preferences and impact the market for lancet used in traditional blood glucose meters.
Rapid Improvements to Provide a Significant Push
In November 2023, Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus on lung disease, announced the validation and launch of a new method of collecting blood specimens for Nodify Lung Nodule Risk Assessment testing. The method uses the FDA-cleared Tasso+™ device, a single-use blood lancing device intended for obtaining capillary whole blood samples from a patient’s upper arm.
The integration of innovative devices like Tasso+™ signals potential growth, as it introduces an efficient and patient-friendly alternative for fetching blood samples, potentially influencing increased adoption and demand in the lancet market.
Increase in FDA Approvals
In October 2023, Sanguina received the approval from the US Food and Drug Administration (FDA) for its haemoglobin test kit, AnemoCheck Home. AnemoCheck Home, which is an in vitro diagnostic device, will be available only through prescription. Sanguina’s disposable test helps users receive precise haemoglobin level readings by carrying out a simple fingerstick blood test. Sanguina is focused on the development of digital and at-home health platforms for quick home-based testing and disease management. The brand is excited to provide a convenient, accurate, and accessible tool to monitor their haemoglobin levels at home. This approval would significantly aid the global lancet market demand as the test requires a simple fingerstick blood sample, propelling the demand for lancets used in home-based testing and aligning with the growing trend of at-home health monitoring and disease management. Globally, around 40% of all children aged 6–59 months, 37% of pregnant women, and 30% of women 15–49 years of age are affected by anaemia.
Global Lancet Market Segmentations
Market Breakup by Type
- Safety Lancet
- Personal Lancet
- Hemoglobin Testing
- Glucose Testing
- Coagulation Testing
- Others
- Hospitals and Clinics
- Diagnostics Centers and Pathology Laboratories
- Home Diagnostics
- Research and Academic Laboratories
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
The growth of the market is primarily driven by the increasing incidences of diabetes and high infectious diseases worldwide. However, the danger of needlestick injuries, the reuse of lancets, and the bad reimbursement situation may act as the major market constraints, hampering the lancet market growth.
North America is anticipated to dominate the regional market due to factors such as the increasing healthcare sector, increasing geriatric population, fast financial development, and increased awareness of diabetes treatment are some of the primary factors, which are aiding in the growth of the North America lancet market growth.
In January 2023, Cipla launched a point-of-care testing device for various non-communicable diseases and other medical conditions. Another addition to its product offerings for diagnostics laboratories, Cipla’s device named Cippoint, offers a wide range of testing parameters including cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers. The device is approved by the European In-Vitro Diagnostic Device Directive, thus ensuring reliable testing solutions.
Cippoint – an immunofluorescence-based quantitative analyser, can help healthcare professionals to get test results in 3 to 15 minutes, thus enabling a faster clinical decision-making process.
The introduction of Cipla's point-of-care testing device could increase the demand for lancets as they are commonly used in devices for blood sampling in point-of-care diagnostics, bolstering the market demand. The focus of Cippoint on accessibility in rural and remote areas is further expected to drive the need for lancets in healthcare settings.
Global Lancet Market: Competitor Landscape
In December 2023, BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced it had received 510(k) clearances from the U.S. Federal Drug Administration (FDA) for a novel blood collection device that obtains blood samples from a fingerstick that produce lab-quality results for some of the most commonly ordered blood tests.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Terumo Corporation
- Bayer AG
- MTD Medical Technology and Devices
- Sarstedt AG & Co. KG
- BD
- Abbott
- F. Hoffmann-La Roche Ltd.
- Greiner Bio-One International GmbH
- Improve Medical
- B. Braun SE
- Medline Industries, Inc.
- Nipro Medical Corporation
- Owen Mumford
- ARKRAY, Inc.
- Bionime Corporation
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Lancet Market Overview
- 3.1 Global Lancet Market Historical Value (2018-2024)
- 3.2 Global Lancet Market Forecast Value (2025-2034)
- 4 Global Lancet Market Landscape
- 4.1 Global Lancet Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Lancet Product Landscape
- 4.2.1 Analysis by Type
- 4.2.2 Analysis by Applications
- 5 Global Lancet Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Model
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Lancet Market Segmentation (218-2034)
- 6.1 Global Lancet Market (2018-2034) by Type
- 6.1.1 Market Overview
- 6.1.2 Safety Lancet
- 6.1.2.1 Side Button Lancet
- 6.1.2.2 Push Button Safety Lancet
- 6.1.2.3 Pressure Activated Safety Lancet
- 6.1.3 Personal Lancet
- 6.2 Global Lancet Market (2018-2034) by Applications
- 6.2.1 Market Overview
- 6.2.2 Hemoglobin Testing
- 6.2.3 Glucose Testing
- 6.2.4 Coagulation Testing
- 6.2.5 Others
- 6.3 Global Lancet Market, by End User
- 6.3.1 Market Overview
- 6.3.2 Hospitals and Clinics
- 6.3.3 Diagnostics Centers and Pathology Laboratories
- 6.3.4 Home Diagnostics
- 6.3.5 Research and Academic Laboratories
- 6.4 Global Lancet Market (2018-2034) by Region
- 6.4.1 Market Overview
- 6.4.2 North America
- 6.4.3 Europe
- 6.4.4 Asia Pacific
- 6.4.5 Latin America
- 6.4.6 Middle East and Africa
- 7 North America Lancet Market (218-2034)
- 7.1 North America Lancet Market (2018-2034) by Type
- 7.1.1 Market Overview
- 7.1.2 Safety Lancet
- 7.1.2.1 Side Button Lancet
- 7.1.2.2 Push Button Safety Lancet
- 7.1.2.3 Pressure Activated Safety Lancet
- 7.1.3 Personal Lancet
- 7.2 North America Lancet Market (2018-2034) by Application
- 7.2.1 Market Overview
- 7.2.2 Hemoglobin Testing
- 7.2.3 Glucose Testing
- 7.2.4 Coagulation Testing
- 7.2.5 Others
- 7.3 North America Lancet Market (2018-2034) by Country
- 7.3.1 United States of America
- 7.3.2 Canada
- 8 Europe Lancet Market (218-2034)
- 8.1 Europe Lancet Market (2018-2034) by Type
- 8.1.1 Market Overview
- 8.1.2 Safety Lancet
- 8.1.2.1 Side Button Lancet
- 8.1.2.2 Push Button Safety Lancet
- 8.1.2.3 Pressure Activated Safety Lancet
- 8.1.3 Personal Lancet
- 8.2 Europe Lancet Market (2018-2034) by Application
- 8.2.1 Market Overview
- 8.2.2 Hemoglobin Testing
- 8.2.3 Glucose Testing
- 8.2.4 Coagulation Testing
- 8.2.5 Others
- 8.3 Europe Lancet Market (2018-2034) by Country
- 8.3.1 United Kingdom
- 8.3.2 Germany
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Others
- 9 Asia Pacific Lancet Market (218-2034)
- 9.1 Asia Pacific Lancet Market (2018-2034) by Type
- 9.1.1 Market Overview
- 9.1.2 Safety Lancet
- 9.1.2.1 Side Button Lancet
- 9.1.2.2 Push Button Safety Lancet
- 9.1.2.3 Pressure Activated Safety Lancet
- 9.1.3 Personal Lancet
- 9.2 Asia Pacific Lancet Market (2018-2034) by Application
- 9.2.1 Market Overview
- 9.2.2 Hemoglobin Testing
- 9.2.3 Glucose Testing
- 9.2.4 Coagulation Testing
- 9.2.5 Others
- 9.3 Asia Pacific Lancet Market (2018-2034) by Country
- 9.3.1 China
- 9.3.2 Japan
- 9.3.3 India
- 9.3.4 Australia
- 9.3.5 ASEAN
- 9.3.6 Others
- 10 Latin America Lancet Market (218-2034)
- 10.1 Latin America Lancet Market (2018-2034) by Type
- 10.1.1 Market Overview
- 10.1.2 Safety Lancet
- 10.1.2.1 Side Button Lancet
- 10.1.2.2 Push Button Safety Lancet
- 10.1.2.3 Pressure Activated Safety Lancet
- 10.1.3 Personal Lancet
- 10.2 Latin America Lancet Market (2018-2034) by Application
- 10.2.1 Market Overview
- 10.3 Latin America Lancet Market (2018-2034) by Country
- 10.3.1 Brazil
- 10.3.2 Argentina
- 10.3.3 Mexico
- 10.3.4 Others
- 11 Middle East and Africa Lancet Market (218-2034)
- 11.1 Middle East and Africa Lancet Market (2018-2034) by Type
- 11.1.1 Market Overview
- 11.1.2 Safety Lancet
- 11.1.2.1 Side Button Lancet
- 11.1.2.2 Push Button Safety Lancet
- 11.1.2.3 Pressure Activated Safety Lancet
- 11.1.3 Personal Lancet
- 11.2 Middle East and Africa Lancet Market (2018-2034) by Application
- 11.2.1 Market Overview
- 11.2.2 Hemoglobin Testing
- 11.2.3 Glucose Testing
- 11.2.4 Coagulation Testing
- 11.2.5 Others
- 11.3 Middle East and Africa Lancet Market (2018-2034) by Country
- 11.3.1 Saudi Arabia
- 11.3.2 United Arab Emirates
- 11.3.3 Nigeria
- 11.3.4 South Africa
- 11.3.5 Others
- 12 Regulatory Framework
- 12.1 Regulatory Overview
- 12.1.1 US FDA
- 12.1.2 EU EMA
- 12.1.3 INDIA CDSCO
- 12.1.4 JAPAN PMDA
- 12.1.5 Others
- 13 Patent Analysis
- 13.1 Analysis by Type of Patent
- 13.2 Analysis by Publication year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 13.7 Analysis by Key Players
- 14 Grants Analysis
- 14.1 Analysis by year
- 14.2 Analysis by Amount Awarded
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Grant Application
- 14.5 Analysis by Funding Institute
- 14.6 Analysis by NIH Departments
- 14.7 Analysis by Recipient Organization
- 15 Funding and Investment Analysis
- 15.1 Analysis by Funding Instances
- 15.2 Analysis by Type of Funding
- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Type of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Supplier Landscape
- 17.1 Terumo Corporation
- 17.1.1 Company Overview
- 17.1.2 Product Portfolio
- 17.1.3 Demographic Reach and Achievements
- 17.1.4 Mergers and Acquisitions
- 17.1.5 Certifications
- 17.2 Bayer AG
- 17.2.1 Company Overview
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Mergers and Acquisitions
- 17.2.5 Certifications
- 17.3 MTD Medical technology and Devices
- 17.3.1 Company Overview
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Mergers and Acquisitions
- 17.3.5 Certifications
- 17.4 Sarstedt AG & Co. KG
- 17.4.1 Company Overview
- 17.4.2 Product Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Mergers and Acquisitions
- 17.4.5 Certifications
- 17.5 BD
- 17.5.1 Company Overview
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Mergers and Acquisitions
- 17.5.5 Certifications
- 17.6 Abbott
- 17.6.1 Company Overview
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisitions
- 17.6.5 Certifications
- 17.7 F. Hoffmann-La Roche Ltd.
- 17.7.1 Company Overview
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Mergers and Acquisitions
- 17.7.5 Certifications
- 17.8 Greiner Bio-One International GmbH
- 17.8.1 Company Overview
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisitions
- 17.8.5 Certifications
- 17.9 Improve Medical
- 17.9.1 Company Overview
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Mergers and Acquisitions
- 17.9.5 Certifications
- 17.10 B. Braun SE
- 17.10.1 Company Overview
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Mergers and Acquisitions
- 17.10.5 Certifications
- 17.11 Medline Industries, Inc.
- 17.11.1 Company Overview
- 17.11.2 Product Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Mergers and Acquisitions
- 17.11.5 Certifications
- 17.12 Nipro Medical Corporation
- 17.12.1 Company Overview
- 17.12.2 Product Portfolio
- 17.12.3 Demographic Reach and Achievements
- 17.12.4 Mergers and Acquisitions
- 17.12.5 Certifications
- 17.13 Owen Mumford
- 17.13.1 Company Overview
- 17.13.2 Product Portfolio
- 17.13.3 Demographic Reach and Achievements
- 17.13.4 Mergers and Acquisitions
- 17.13.5 Certifications
- 17.14 ARKRAY, Inc.
- 17.14.1 Company Overview
- 17.14.2 Product Portfolio
- 17.14.3 Demographic Reach and Achievements
- 17.14.4 Mergers and Acquisitions
- 17.14.5 Certifications
- 17.15 Bionime Corporation
- 17.15.1 Company Overview
- 17.15.2 Product Portfolio
- 17.15.3 Demographic Reach and Achievements
- 17.15.4 Mergers and Acquisitions
- 17.15.5 Certifications
- 18 Global Lancet Market - Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
- 20.1 Very Small Companies
- 20.2 Small Companies
- 20.3 Mid-Sized Companies
- 20.4 Large Companies
- 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
- 21.1 Government Funded
- 21.2 Private Insurance
- 21.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
